More Ways to Connect
  LinkedIn Twitter YouTube Instagram

University of Cincinnati Academic Health Center
Publish Date: 06/10/99
Media Contact: AHC Public Relations, (513) 558-4553
PDF download
RSS feed
related news
share this
New Study Shows Long-Term Benefit of t-PA

Cincinnati—A study published in the June 10 edition of The New England Journal of Medicine found that patients who were treated with tissue plasminogen activator (t-PA) within three hours after the onset of symptoms of acute ischemic stroke were at least 30 percent more likely than patients who received placebo to have minimal or no disability 12 months after the stroke. This research study is a follow-up project to the 1995 National Institute of Neurological Disorders and Stroke study that showed the short-term benefits of t-PA in stroke treatment.

"The first study demonstrated the short-term benefit of t-PA in patients experiencing acute ischemic strokes," says Joseph P. Broderick, MD, professor of neurology at the University of Cincinnati (UC) College of Medicine, co-author of the follow-up study, and member of the Greater Cincinnati/Northern Kentucky Stroke Team. "This follow-up study shows the long-term effectiveness of this treatment in lessening the severity of disabilities caused by strokes."

The researchers collected outcome information from 624 patients who participated in the 1995 study. Of the patients, 150 were treated by the Greater Cincinnati/Northern Kentucky stroke team. The outcome comparison also revealed no significant difference in 12 month mortality rates between the two groups. The rate of recurrent stroke at 12 months was also similar for the patients who received t-PA and those that received the placebo.

These new results show a long-term benefit of t-PA for patients. These results also led researchers to credit t-PA with reducing health care costs and improving the quality of life for patients who receive this new treatment.

 back to list | back to top